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Abstract:  
 
Background: The aim of the present study was to appraise retrospectively the 
influence of valproate (VPA) and antidepressants (ADs) on the steady-state 
plasma concentrations of clozapine (CLZ), the prototype of various second-
generation antipsychotics (SGAs), norclozapine (NCLZ, its main metabolite), and 
their ratio (NCLZ/CLZ). 
Methods: Sixty-seven psychotic patients with a prevalent diagnosis of bipolar 
disorder (BD) were studied. We then analyzed data altogether and subdivided 
them into four groups, according to pharmacological treatments: #1 CLZ (n=21), 
#2 CLZ plus antidepressants (ADs) (n=13), #3 CLZ plus VPA (n=16), and #4 
CLZ plus ADs plus VPA (n=17). 
Results: Firstly, significant positive correlations between CLZ plasma parameters 
(ng/ml) and the drug daily dosages (mg/kg body weight) (n=67) were observed 
(Spearman, rCLZ=0.49, rNCLZ=0.43, P<.001; rratio=0.31, P=.011). We then 
normalized by given doses CLZ and NCLZ plasma levels, natural log transformed 
them, and carried out ANOVA factor analyses followed by pairwise comparisons, 
performed on the four groups and the three CLZ parameters. We identified 
significant drug effects on: 1) CLZ plasma levels, significantly higher in group #2 
vs. group #1, 2) NCLZ/CLZ ratio, lower in group #2 vs. group #1 and #3. 
Significant drug × gender interactions were observed in group #3, showing higher 
NCLZ levels and NCLZ/CLZ ratios in men compared to women. 
Conclusions Despite its inherent limitations, this observational study confirms the 
significant increase of plasma CLZ concentrations and reduction of NCLZ/CLZ 
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ratio when this drug is co-administered with ADs (group #2), an  effect apparently 
counteracted by VPA (group #4). The drug × gender interactions in patients 
taking both CLZ and VPA (group #3) warrant further prospective study.  
Keywords: Clozapine, Valproate, Antidepressants, Clozapine Plasma Parameters. 
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Introduction 
 
Although several novel second-generation antipsychotics (SGAs) are currently 
available,1 the prototypical clozapine (CLZ) remains the gold standard treatment 
for both positive and negative refractory symptoms in schizophrenia.2-7 This is 
mainly attributable to the proven greater capacity of this drug to prevent patients’ 
relapses, as well as to improve their social and occupational adjustments.8-11. 
However, CLZ is not without adverse effects. The most relevant ones are 
neutropenia and agranulocytosis,12  the later occurring in about 0.5% of treated 
patients, with a mortality rate of 3%,13 thus requiring mandatory periodic blood 
tests. Too high daily dosages, a reduced renal clearance, characterized by 
abnormal metabolic profiles, as shown by dramatically increased plasma 
concentrations of the desmethylated metabolite norclozapine (NCLZ), have been 
linked to the augmented incidence of agranulocytosis,12,14 as well as to the 
higher probability at developing seizures, delirium, confusion,15-19 and/or 
inflammation states.20 Therefore, with no doubt, the assessment of plasma levels 
of CLZ and NCLZ would represent a helpful tool for the management of patient’s 
compliance, presence of adverse effects, unusual metabolic activities, 
pharmacological interactions, toxicity, possibly arising during the treatment with 
this drug. In effect, CLZ therapeutic monitoring would contribute to attain the 
rationalized planning of daily dosages and, possibly, the optimization of clinical 
responses.15, 21, 22  
A high inter-individual variability of steady-state CLZ plasma levels has been 
observed even at the same given daily dosage,19,23, 24 a finding which makes 
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difficult to predict the circulating concentrations of this drug, also implying its 
complex biotransformation and clearance.25, 26 Some authors pointed out the 
current limits of CLZ therapeutic monitoring and the need of additional 
investigations.2 
Indeed, present knowledge on CLZ metabolism regulation is still incomplete: in 
particular, there is little information on the disposition and biotransformation of 
this drug with respect to other relevant side effects, such as obesity, diabetes, and 
myocarditis, that may lead to its discontinuation. 1, 27 
Consequently, the measure of CLZ plasma levels represents a current challenging 
issue in clinical psychiatry, and the full elucidation of factors potentially able to 
alter CLZ biotransformation would allow to apply a more robust and valuable 
therapeutic monitoring. 
Pharmacological interactions are among the main causes of variation of CLZ 
plasma concentrations. Indeed, beyond the divergent views on the relative 
advantages of CLZ on polypharmacy,28,,29 as a matter of fact, this SGA is 
frequently used in combination with other psychotropic compounds. 
Combinations of SGAs and/or FGAs are, for instance, used for improving 
compliance or for CLZ augmentation strategies in schizophrenic patients.30-32 
Further, CLZ is often co-administrated in schizoaffective and mood disorders 
with treatment-refractory psychotic symptoms33 while suggesting the helpfulness 
of therapeutic drug monitoring (TDM) also in these conditions.34 
Valproate (valproic acid, VPA) is a drug frequently co-prescribed with CLZ to 
reduce the risk of seizures or as a mood stabilizer (MS) in BD.19, 35, 36 Data on 
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the effect of VPA on CLZ metabolism are still conflicting,37-46 and such 
controversies have been related to the complexity of CLZ metabolism.19 
A recent study showed the propensity of VPA at enhancing CLZ metabolism46 by 
applying a multivariate mathematical model. In addition to VPA, antidepressants 
(ADs), like selective serotonin reuptake inhibitors (SSRIs), may also be used in 
association with CLZ in the treatment of mood disorders with psychotic 
symptoms: in most studies, they were found to reduce CLZ metabolism.47-50 
Given the  contradictory data available, our study aimed at appraising the 
influence of VPA and ADs, administered separately or together, by a 
retrospective and naturalistic investigation on the plasma steady-state a 
concentrations of CLZ and NCLZ (ng/ml), together with their ratio (NCLZ/CLZ), 
in a cohort of patients suffering from psychotic mood disorders. The parameter 
ratio is considered  to be an index of CLZ metabolism.51 
 
Material and Methods 
Subjects 
Patients were selected during outpatient examination or hospitalization at the 
Psychiatry Unit of the “Santa Chiara” Hospital and University Center, University 
of Pisa. Patients’ inclusion criteria were as follows: an established diagnosis of a 
mood or schizoaffective disorder carried out by skilled psychiatrists according to 
DSM-IV R criteria52; treatment with a fixed CLZ dosage for at least 15 days 
from the beginning of the therapy or from appreciable changes in daily dosages, 
considering the approximate CLZ and NCLZ half-lives are 12 and 22 hours, 
respectively 53; the accessibility to records of CLZ and NCLZ plasma levels 
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measured at steady state; a history of good health conditions before and during 
the monitoring period, as shown by results of blood and urine tests. Patients 
following a concomitant treatment with a stable dose of ADs, VPA, or both 
compounds were included. Exclusion criteria were as follows: history of alcohol 
or drug abuse; neurological and neurodegenerative CNS disorders; altered routine 
laboratory tests; concomitant treatments with MSs other than VPA, such as 
carbamazepine and lamotrigine; concomitant treatments with other drugs such as 
antibiotics, anti-inflammatory and painkiller drugs. Smoking habit was also 
included. Smokers were included in this study when receiving higher CLZ 
dosages than required. Patients’ caffeine assumption did not exceed 400 mg/die.23, 
25, 54, 55 
All patients presented severe psychotic symptoms or a high risk of relapse, 
defined by delirium, paranoia, significant social/cognitive impairment, very low 
quality of life, and elevated propensity to suicide. All patients had signed an 
informed consent form for the use of blood withdraws for the analysis of CLZ 
plasma levels. 
Data from medical records reporting a CLZ treatment in association with 
benzodiazepines (BDZs) and/or lithium were  included in the analysis, due to 
their  minor  pharmacological interaction with CLZ metabolism.37, 51 We also  
included  patients taking haloperidol, which was prescribed to increase 
compliance or to augment CLZ efficacy, at doses not exceeding 5 mg/day. 
Measurement of clozapine and norclozapine concentrations in plasma by 
HPLC 
Blood sampling, plasma preparation, and measurements of CLZ and NCLZ levels 
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were performed as previously described.56 CLZ and NCLZ plasma levels, 
reported in patients’ database as ng/ml, were used as such or transformed into 
their ratio, plasma NCLZ to CLZ (NCLZ/CLZ). We used the ratio as  an index of 
the drug metabolism.. 
Statistical analyses 
All demographic, clinical, and laboratory data were presented as mean ± standard 
deviation (SD), variation range (min and max values), or medians, a s  
required. The Spearman’s test was carried out for correlations between CLZ and 
NCLZ plasma levels and CLZ  dose and reported as CLZ daily dose (mg/kg body 
weight; bw).54 Correlations were followed by linear regression analyses to yield 
R-squared determination coefficients (r2). For correlation and linear regression 
tests, plasma CLZ and NCLZ levels were directly evaluated as ng/ml, without 
normalization for a given dose.54 
To  evaluate the influence of different pharmacological treatments, patients were  
divided into four groups: #1 CLZ alone (n=21); #2 CLZ plus ADs, n=13); #3 
CLZ plus VPA (n=16); #4 CLZ plus ADs plus VPA (n=17). For comparisons, 
CLZ and NCLZ were considered as ng/ml/(mg/kg bw), or plasma levels at a 
given dose,54 while the NCLZ/CLZ ratio was treated as such. Since CLZ plasma 
parameters are skewed to the right and not normally distributed, we decided to 
transform them into natural logarithms (ln), in order to apply parametric statistics. 
This was essentially done to better synthesize results as well as to use the factorial 
ANOVA model, which was considered more suitable for our aims. Specifically, 
we utilized factorial ANOVA followed by pairwise comparisons to study the 
influence of drug, gender, age, and smoking habit and their possible interactions 
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on CLZ, NCLZ, and ratio as ln. 
All statistics were carried out using the SPSS Statistical Package for Social 
Sciences (SPSS-20.0, Chicago, Ill., USA)57 and the Graph-Pad Prism version 5.0 
(Graph-Pad Software, San Diego, USA).58 The two-tailed statistical significance 
was set at P=.05. 
 
 
 
Results 
 
Sixty-seven patients were included in the investigation. From records, 80% of 
patients were outpatients. Table 1 summarizes patients’ demographic data, 
administered CLZ daily dosages, and the antipsychotic plasma parameters, 
normalized for dose-weight or not. There was a preponderance of women (about 
2:1, W:M). Patients’ age was considered in respect to the study of Haring et al. 
(1989) and its potential effect on CLZ metabolism23: subjects were thus also 
divided into those aged below 35 and above 35 years, respectively, lower and 
equal or higher than the mean age of present cohort. An equal proportion of 
subjects aged below and above 35 years defined our cohort. 
Patients’ clinical features and treatment subgroups 
 
Fifty-nine patients received a diagnosis of BD (20 BDI; 13 BDII ; 20 non-
otherwise specified, NSBD and six mixed state), while some patients  were 
suffering from major depression (n=5, MD) and schizoaffective disorder (n=3, 
SZD). Table 2 presents the main features of patients within each of four groups. 
BD1 was a frequent diagnosis in group #3 (CLZ plus VPA), while an equal 
number of patients with BD1 and BD2 was found in group #1 (CLZ alone). 
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Diagnosis of mixed state, depression, or schizoaffective disorder occurred in 
group #2 (CLZ plus ADs) and #3, whilst BDNS was prevalent in group #4 (CLZ 
plus VPA plus ADs). CLZ daily doses (mg/day) or daily dose corrected for 
weight ((mg/kg)/day) in the four groups are also reported: lower mean doses were 
administered to patients taking ADs, thus belonging to group #2 and #4, a 
difference which did not  achieve, however, statistical significance. 
Table 2 also shows gender, age, and smoking habit distribution in each of the four 
groups of patients in respect to treatment. Table 2 also displays age values divided 
into below and above 35 years. Information on smoking behavior and treatment 
duration was available, respectively, for 63 and 40 of the 67 subjects. Group #1 
and #3 were balanced for gender, smoking behavior, and age, whereas group #2 
and #4 were composed mainly by women younger than 35 years in group #2, 
older than 35 in group #4; group #4 was also defined by a higher number of 
smokers (11 S: 6 NS) than the others. 
In terms of pharmacological treatment, 33 patients were taking VPA (daily doses 
200-1250 mg, mean ± SD: 588 ± 267 mg) and 34 were not taking VPA. Thirty 
patients were taking ADs, either SSRIs or tricyclics (TCAs), in combination with 
CLZ alone (n=13) or with CLZ plus VPA (n=17). The SSRIs were as follows: 
fluvoxamine (n=11, 150 mg/day), paroxetine (n=7, 45 mg/day), sertraline (n=4, 
75 mg/day), and fluoxetine (n=3, 20 mg/day). The TCAs were trimipramine 
(n=7, 90 mg/day), imipramine (n=4, 150 mg/day), clomipramine (n=1, 100 
mg/day), and amitriptyline (n=1, 150 mg/day).  
Twenty-two patients were taking haloperidol. More than half of group #1 
patients, two of group #2, four of group #3, and three of group #4 were also 
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treated  with FGAs. Nineteen patients were receiving doses lower than 5 mg/day 
of haloperidol (2.5 ± 1.5 mg/day (mean ± SD)). 
No significant correlation was observed herein between age, body weight, and 
CLZ plasma parameters. 
Dose-level correlations 
 
Figure 1 (A,B) depicts the significant Spearman’s correlations between plasma 
levels (ng/ml) of CLZ, NCLZ, and  dose, CLZ mg/kg bw, in the whole study 
group. Significant and positive correlations were found for CLZ and NCLZ 
plasma levels. Correlations remained significant for CLZ and NCLZ plasma 
levels when patients were analyzed considering their treatment without (n=34) or 
with VPA (n=33), separately (data not shown). Patients treated with (n=30) and 
without ADs (n=37) also showed positive correlations between CLZ, NCLZ 
plasma levels, and given dose (data nor shown). 
ANOVA factorial test: effect of the different drug treatments on CLZ 
metabolism 
 
Figure 2 (A-D) shows CLZ parameters, corrected by the given dose (mg/kg), 
obtained in the various groups. After natural log transformation of data, the 
ANOVA factorial test, followed by pairwise comparisons, revealed a significant 
main effect of drug on 1) CLZ plasma levels (ln), F(3.59) = 2.77, P=.049, 
significantly higher in group #2 than group #1 (P=.025) after the Bonferroni post-
hoc test, 5.32 ± 1.20 vs. 4.30 ± 0.90; 2) ratios (ln), F(3.59) = 4.56, P=.006, 
significantly lower in group #2 vs. group #1 (P=.001) and #3 (P=.016) after 
Bonferroni post-hoc test, −1.94 ± 0.99 vs. −1.0 ± 0.46 and −1.15 ± 0.76. 
ANOVA factorial tests: interactions between different treatments and 
12  
individual variables 
 
Despite possible biases due to unmatched groups or missing values, we examined 
the impact of age, gender, and smoking behavior on plasma CLZ parameters in 
the four groups, by means of the ANOVA factorial model. Although treatment 
duration represents a potentially relevant influencing factor of plasma CLZ 
variation, it was not possible to evaluate its  impact herein, since precise 
information was available for 40 patients only. 
No significant drug × age interaction was detected, suggesting the hierarchical 
influence of AD treatment vs. age on CLZ plasma parameters. Figure 3 (A,B) 
depicts NCLZ plasma levels, corrected by the given dose (mg/kg), and 
NCLZ/CLZ ratio values obtained in group #3, where a significant factorial 
ANOVA analysis was reported on ln transformed data and in respect to gender. 
Results revealed significant drug × gender interactions on 1) NCLZ levels ((ln), 
F(3.59) = 4.01, P=.012), higher values in men than women in the CLZ-VPA 
group (group #3), 4.19 ± 0.95 vs. 2.82 ± 0.65, P=.004; 2) ratios (ln), F(3.59) = 
3.20, P=.03, lower value in men than women, −1.57 ± 0.39 vs. −0.61 ± 0.79, in 
group #3, P=.007, corresponding to higher NCLZ/CLZ ratio in men than women 
(Fig. 3B). 
The factorial analysis applied for smoking behavior showed no significant drug × 
smoking interaction (P>.05). 
 
Discussion 
 
The management of treatment-refractory psychotic patients still represents a 
major  challenge in psychiatric care.59  Although newer  SGAs have been 
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introduced into  clinical practice,60 CLZ is considered the first-choice therapeutic 
strategy in such severe conditions.6 However, despite its recognized higher 
effectiveness compared with that of other SGAs, the use of CLZ is mainly limited 
by its side effects and the need of monitoring white blood cell counts.60 The 
availability of CLZ TDM  would considerably contribute to a more appropriate 
use of CLZ. Daily dosages ranging from 300 to 600 mg, together with a window 
of CLZ plasma levels, ranging between 250 and 420 ng/ml, have been associated 
with a higher probability to obtain satisfactory clinical responses in schizophrenic 
patients without  significant side effects, 21, 22, 61-64  although this is not 
universally accepted .27 Similarly, the reported high inter-individual variability of 
the drug’s plasma levels somehow continues to limit their predictive impact 
during  treatment. This variability has been attributed to a number of factors 
essentially linked to pharmacogenomics, epigenetics, and patients’ lifestyle65 . 
This underlines the need to obtain a more detailed understanding of the 
variables affecting CLZ plasma levels: a complete and appropriate monitoring of 
the SGAs can pave the way toward ever more tailored and personalized 
antipsychotic treatments. 
Of note, even therapeutic ranges have been found to change according to different 
patients’ diagnoses. Indeed, CLZ low plasma levels (25 ng/ml) are considered the 
threshold for an effective response in patients with Parkinson’s disease and L-
dopa-induced psychosis.66, 67 Doses ranging between 25 and 100 mg/day may 
improve psychotic symptoms in borderline personality disorder.68 Furthermore, 
dosages lower than 250 mg/day have been reported effective in BD patients.69-71 
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Bipolar patients were also found to respond more rapidly to CLZ than 
schizophrenic patients .69 Other studies have reported improvement at relatively 
lower CLZ daily dosages or plasma levels when another SGA is co-
administered.72-74 
Furthermore, although not definitely proven,75 the metabolite NCLZ has been 
shown to elicit specific pharmacological CNS actions, and, in particular, it 
behaves as an agonist of muscarinic M1 receptors, thus suggesting that it may 
contribute to the therapeutic effect of the parent compound.76-81 CLZ and NCLZ 
plasma/serum levels also reflect the successful passage across the brain-blood 
barrier of these compounds and the effective occupation of neuroreceptors.82 
Consequently, the CLZ metabolism indexNCLZ/CLZ 51,83 or the reciprocal 
CLZ/NCLZ,84 might perhaps be considered an optimal indicator of patients’ 
response. 
Interestingly, some authors described a relationship between the measure of 
NCLZ ratio values and working memory performances in treated patients.85 
Ratio values change as a function of blood withdraw timings, for instance, when 
samplings are  obtained shortly after a relevant change of daily dosage and/or just 
after the last drug administration. These indexes are also affected by the analytical 
method  used, or the procedure employed to extract CLZ and NCLZ from the 
biological matrix51,56,61,86 or by the interactions with other drugs.45, 84, 87 
VPA is one of the drugs most used in combination with CLZ.19 VPA is 
metabolized by CYP2C9, a CYP450 isoform involved also in CLZ metabolism. 
Studies on the pharmacological interactions between VPA and CLZ, mostly 
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performed in schizophrenic patients, provided contrasting data: two reports 
described a moderate increase of CLZ levels (39% and 20%) after at least one 
week of steady dose treatment,37, 40 without reaching statistical significance. 
Wong et al.43 observed increased CLZ plasma levels and a decrease of 
NCLZ/CLZ ratio in Chinese schizophrenic patients treated with VPA. By 
contrast, Finley and Warner38 noted that VPA induced CLZ metabolism in a 
small sample of patients (n=4). Another study reported a 15% decrease of CLZ 
levels after VPA addition,39 while, in a case report, plasma CLZ concentration  
was decreased after VPA administration.88 Others, in a large group of patients, 
showed no effect of VPA on CLZ levels, similarly to that observed in a cohort of 
BD patients.41 As reviewed by Varma et al.,19 opposite results were reported in 
smoker and non-smoker  patients, as nicotine is an inducer of VPA metabolism .44 
A more recent and comprehensive investigation carried out in 151 patients 
supports the potential of VPA as an inducer of CLZ metabolism, by using a 
multivariate mathematical model to exclude confounding factors.45, 46  
The present observational study addresses the question of the influence of both 
VPA and ADs on CLZ and NCLZ plasma levels, without searching the “true” 
effect of co-administered drugs on CLZ metabolism, but rather exploring their 
ensuring effect on psychotic patients, mainly suffering from BD.  
Our study reports  on various  findings. Firstly, we confirmed the presence of a 
significant positive correlation between CLZ  daily doses and CLZ or NCLZ 
plasma levels, in agreement with naturalistic and prospective studies.23, 51, 54, 
89-93 Our dose-level correlation coefficients are within values previously 
reported,  even if there are significant differences among them. This may be due 
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to the different compliance or individual variables among the patients examined. 
In addition, normalization or not of daily dosage for body weight, or the different 
sample sizes are also potential sources of variance. 
To appraise the presence of possible pharmacological interactions of CLZ with 
ADs, VPA, or both drugs and to better synthetize statistics and ensuing results, 
we thus normalized CLZ and NCLZ for given doses and transformed all the three 
CLZ plasma parameters into natural logarithms (ln).89 This permitted to perform 
parametric factorial ANOVA analyses and compare them and the four treatment 
groups. Only patients from group #2 (taking CLZ plus ADs) reported significant 
differences: in particular, they displayed higher CLZ plasma levels together with 
a reduced NCLZ/CLZ ratio, confirming the AD-dependent competitive inhibition 
of CLZ metabolism37, 49,50 Not surprisingly, CLZ augmentation by the SSRI 
fluvoxamine has been proposed as a safe strategy to reach CLZ therapeutic effects 
at lower doses.50  
Our ANOVA results, together with the strong positive correlations between CLZ 
daily doses and NCLZ plasma levels or ratio in patients taking ADs (authors’ 
observation, data not shown), suggest to investigate also these parameters as 
possible predictors of an effective and safe CLZ augmentation strategy in mood 
disorders with psychotic features. No appreciable difference was found between 
CLZ plasma parameters measured in patients treated or not with VPA, 
accordingly to our previous study41. However, group #4 taking VPA plus ADs 
showed greater ratio values than group #2, while suggesting the potential of VPA 
at somehow counteracting AD-mediated inhibition of CLZ metabolism. Indeed, if 
there had been a VPA-mediated inhibitory effect on CLZ metabolism and a 
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synergic VPA-AD action, we would have expected lower NCLZ/CLZ ratio values 
in group #4, at least comparable to those reported in group #2. Moreover, group 
#4 was composed of older subjects than group #2 supposed to have higher CLZ 
levels.23 In a previous study, we had evaluated the influence of patient-related 
variables such as age, gender, or smoking behavior on CLZ plasma parameters, 
e.g., CLZ and NCLZ plasma levels, their sum and ratio, while reporting moderate 
effects of gender and smoking on CLZ metabolism. The action of smoking  on 
sum (CLZ + NCLZ) reported herein confirms decreased CLZ plasma levels, as 
already reported in a meta-analysis carried out in a larger cohort of patients.94 By 
using a different approach and applying parametric statistics, we observed 
significant drug × gender interactions only in group #3 taking CLZ plus VPA, a 
group matched for age, gender, and smoking habit. This finding needs, however, 
replication and further study, since the observed drug × gender interaction could 
also be due to clinical factors, such as different clinical history or treatment 
duration in the two sexes. As observed for patients co-treated with ADs, the 
significant variations of NCLZ and ratio in VPA-medicated subjects suggest that 
these two parameters deserve additional investigation on their possible use for 
CLZ TDM. 
 
Conclusions 
 
The overall findings of the present study carried out in patients suffering from 
psychotic mood disorders, mainly BD, confirm the significant increase of plasma 
CLZ concentrations and reduction of NCLZ/CLZ ratio when this drug is co-
administered with ADs, while VPA appears to counteract this effect. In patients 
taking both CLZ and VPA a drug × gender interactions was revealed, with men 
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showing higher NCLZ levels and NCLZ/CLZ ratio than women. This is an 
intriguing result that needs to be further investigated in future studies aimed at 
improving and tailoring antipsychotic treatments. 
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 Figure legends 
 
Figure 1: Spearman correlations between n clozapine (CLZ) daily dosage (mg/kg bw) and: A) CLZ, and B) norclozapine (NCLZ). (***): 
Significant positive correlation, P<.0001; (*): significant positive correlation, P<.05. R2: R-squared determination coefficients after linear 
regression analysis. The straight line represents the linear regression fit. 
 
Figure 2: Clozapine (CLZ) plasma parameters in the 4 groups of patients, in respect to pharmacological treatments. Data are the mean ± 
SD (median). A) CLZ plasma levels, ng/ml/(mg/kg), were: group #1, 106.3 ± 92.57 (84); group #2, 389.2 ± 474.8 (183.4), group #3, 
128.7 ± 95.37 (102), group #4, 136.9 ± 94.48 (105); B) norclozapine (NCLZ levels), ng/ml/mg/kg, were: group #1, 52.07 ± 73.53 (32.8); 
group #2, 46.08 ± 51.87 (18.12); group #3, 52.18 ± 62.14 (30); group #4, 30.11 ± 19.68 (25); and C) the ratio NCLZ/CLZ was: group #1, 
0.4067 ± 0.21 (0.39); group #2, 0.224 ± 0.23 (0.16); group #3, 0.458 ± 0.616 (0.29); group #4, 0.298 ± 0.202 (0.23). 
 
Figure 3: NCLZ/CLZ ratios and NCLZ plasma levels in women and men from the 4 treatment groups. Data are the mean ± SD (median). 
A) Women norclozapine/clozapine (NCLZ/CLZ) ratios were mean ± SD (median): group #1, 0.47 ± 0.24 (0.45); group #2, 0.25 ± 0.26 
(0.16); group #3, 0.22 ± 0.08 (0.23); group #4, 0.29 ± 0.23 (0.21); men ratios were mean ± SD (median): group #1, 0.31 ± 0.11 (0.33); 
group #2, 0.13 ± 0.04 (0.14); group #3, 0.76 ± 0.86 (0.48); group #4, 0.32 ± 0.09 (0.33). B) Women NCLZ plasma levels, ng/ml/mg/kg, 
were: group #1, 60.4 ± 84.0 (38); group #2, 48.4 ± 57.3 (20); group #3, 20.2 ± 12.8 (20.9); group #4, 26.9 ± 17.0 (21.6); men NCLZ plasma 
levels were: group #1, 38.7 ± 55.0 (16); group #2, 38.3 ± 35.0 (18); group #3, 93.3 ± 77.0 (49); group #4, 37.8 ± 25.0 (34.6). 
